Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $467.00 Price Target at Barclays

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by analysts at Barclays from $435.00 to $467.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the pharmaceutical company’s stock. Barclays‘s price objective suggests a potential upside of 3.05% from […]